MAIA Biotechnology Inc. (MAIA)
1.60
-0.03 (-1.84%)
At close: Mar 28, 2025, 3:59 PM
1.62
1.25%
After-hours: Mar 28, 2025, 06:55 PM EDT
Company Description
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer.
Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.
The company was founded in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology Inc.
| Country | United States |
| IPO Date | Jul 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Vlad Vitoc M.B.A., M.D. |
Contact Details
Address: 444 West Lake Street Chicago, Illinois United States | |
| Website | https://www.MAIABiotech.com |
Stock Details
| Ticker Symbol | MAIA |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001878313 |
| CUSIP Number | 552641102 |
| ISIN Number | US5526411021 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, Chief Executive Officer & Chairman of the Board of Directors |
| Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
| Jeffrey C. Himmelreich | Head of Finance |
| Linda Moreira | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2025 | 8-K | Current Report |
| Mar 26, 2025 | 424B5 | Filing |
| Mar 21, 2025 | 8-K | Current Report |
| Mar 21, 2025 | 10-K | Annual Report |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 05, 2025 | 4 | Filing |
| Mar 05, 2025 | 4 | Filing |
| Mar 05, 2025 | 4/A | [Amend] Filing |
| Mar 05, 2025 | 4/A | [Amend] Filing |
| Mar 04, 2025 | D | Filing |